Skip to main content
. 2018 Jun 26;2018:8293594. doi: 10.1155/2018/8293594

Table 2.

Baseline characteristics of participants.

characteristics Group control
(n=36)
Group treatment
(n=35)
P-Value
Age(years) 59.8±13.3 61.7±14.9 0.560
Male (n,%) 19(52.8%) 16(45.7%) 0.552
APACHEII 18.1±3.9 18.9±4.2 0.391
TCM quantitative score of intestinal dysfunction 10.5±3.0 9.8±2.7 0.901
Delay between admission and inclusion(hours) 12.8±5.1 11.9±4.8 0.896
Type of infection (n, %)
 Pneumonia 16(44.4%) 18(51.4%) 0.556
 Peritonitis 7(19.4%) 7(20.0%) 0.953
 CRBSI 6(16.8%) 4(11.4%) 0.526
 Urinary tract infection 7(19.4%) 6(17.2%) 0.802
Dachenqi Decoction (as needed)
 Patients administrated ≥ 1 dose (n, %) 29(80.6%) 26(74.3%) 0.527
 The periods from administration of Dachenqi 20.2±3.4 15.8±2.6 0.001
 Decoction to defecation (hours)
Days on MV 8.3±2.1 7.7±2.0 0.260
Length of stay in ICU(days) 13.9±2.7 13.6±2.8 0.601
28-day mortality% (n) 41.7%(15) 37.1%(13) 0.697

APACHE II: acute physiology and chronic health evaluation; CRBSI: catheter related bloodstream infection; MV: mechanical ventilation; ICU: intensive care unit.